DelveInsight’s ‘Retinitis Pigmentosa Pipeline Insight 2022‘ report provides comprehensive global coverage of available, marketed, and pipeline Retinitis Pigmentosa therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Retinitis Pigmentosa pipeline domain.
Key Takeaways from the Retinitis Pigmentosa Pipeline Report
-
Over 45+ companies and 45+ pipeline drugs pipeline therapies are in various stages of development, and their anticipated acceptance in the Retinitis Pigmentosa market would significantly increase market revenue.
-
Leading Retinitis Pigmentosa companies developing novel drug candidates to improve the Retinitis Pigmentosa treatment landscape include Bogen, Neurotech, Ionis Pharmaceuticals Novartis Pharmaceuticals, Nacuity Pharmaceuticals, and many others.
-
Promising Retinitis Pigmentosa pipeline therapies in various stages of development include BIIB-112, QR 1123, and many others.
Retinitis Pigmentosa Overview
Retinitis pigmentosa is an umbrella term for a group of hereditary progressive retinal disorders that cause progressive degeneration of the retina. The disease is inherited as autosomal recessive, autosomal dominant, or X-linked recessive traits. Signs of retinitis pigmentosa usually appear during childhood or adolescence. Common symptoms include difficulty seeing at night and a loss of side (peripheral) vision. RP is diagnosed by electroretinography (ERG), visual field testing, retinal imaging, fundus auto-fluorescence (FAF), and genetic testing. Currently, there is no therapy that stops the evolution of pigmentary retinopathies or restores vision. Management of retinitis pigmentosa includes dietary supplements, ozone therapy, surgery, etc. Gene therapy-based treatments are under research focus for the treatment of Retinitis pigmentosa.
Retinitis Pigmentosa Pipeline Analysis: Drug Profile
IIB-112: Biogen
BIIB-112 (formerly called NSR-RPGR) consists of a standard AAV8 vector carrying a codon-optimized RPGR gene. BIIB112 is in phase II clinical studies for X-linked retinitis pigmentosa treatment. In September 2018, NSR-RPGR was granted orphan drug designation for the treatment of inherited retinal dystrophies due to defects in the RPGR gene from the U.S. Food and Drug Administration.
QR 1123 (formerly ISIS RHO 2.5Rx): Ionis Pharmaceuticals
QR 1123 (formerly ISIS RHO 2.5Rx) is an antisense oligonucleotide, designed to specifically target the mutant P23H messenger ribonucleic acid (mRNA) in order to reduce the expression of the P23H protein selectively while preserving the expression of the wild type (WT) rhodopsin (RHO) protein. The therapy is currently in Phase II clinical evaluation for the treatment of Retinitis Pigmentosa. In November 2019, ProQR Therapeutics announced that it received an Orphan Drug designation (ODD) from the Food and Drug Administration (FDA) for QR-1123. QR-1123 was in-licensed from Ionis Pharmaceuticals in 2018. QR-1123 has also received Fast Track designation from the FDA.
Discover more about the emerging Retinitis Pigmentosa drugs @ Retinitis Pigmentosa Treatment Drugs
Retinitis Pigmentosa Pipeline Therapies and Key Companies
-
BIIB-112: Biogen
-
QR 1123 (formerly ISIS RHO 2.5Rx): Ionis Pharmaceuticals
-
And many others
Retinitis Pigmentosa Pipeline Therapeutics Assessment
by the Route of Administration. Products have been categorized under various ROAs such as
-
Oral
-
Parenteral
-
Intravitreal
-
Subretinal
-
Topical
-
Molecule Type
Products have been categorized under various Molecule types such as
-
Monoclonal Antibody
-
Peptides
-
Polymer
-
Small molecule
-
Gene therapy
Product Type
Drugs have been categorized under various product types like Mono, Combination, Mono/Combination.
Scope of the Retinitis Pigmentosa Pipeline Report
-
Coverage: Global
-
Key Retinitis Pigmentosa Companies: Biogen, Neurotech, Ionis Pharmaceuticals, Novartis Pharmaceuticals, and many others
-
Key Retinitis Pigmentosa Pipeline Therapies: BIIB-112, QR 1123, and many others.
Find out more about the Retinitis Pigmentosa treatment options in development @ Retinitis Pigmentosa Clinical Trials
Table of Contents
1. Introduction of Retinitis Pigmentosa
2. Executive Summary of Retinitis Pigmentosa
3. Overview of Retinitis Pigmentosa
4. Pipeline Therapeutics of Retinitis Pigmentosa
5. Late-Stage Products (Phase III) of Retinitis Pigmentosa
6. Mid-Stage Products (Phase II) of Retinitis Pigmentosa
7. Early Stage Products (Phase I/II) of Retinitis Pigmentosa
8. Preclinical Stage Products of Retinitis Pigmentosa
9. Discovery Stage Products of Retinitis Pigmentosa
10. Therapeutic Assessment of Retinitis Pigmentosa
11. Inactive Products of Retinitis Pigmentosa
12. Collaborations Assessment- Licensing / Partnering / Funding of Retinitis Pigmentosa
13. Unmet Needs of Retinitis Pigmentosa
14. Market Drivers and Barriers of Retinitis Pigmentosa
15. Appendix of Retinitis Pigmentosa
16. About DelveInsight
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/